Resources

Diabetes

By MMIT
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncol...
0 Comments
© 2024 MMIT

Post-Launch Tracking Surveys

By MMIT
Learn how a pharma company partnered with MMIT’ to understand payer perceptions of its brand over time as competitors enter the market....
0 Comments
© 2024 MMIT

Value Proposition Message Testing

By MMIT
Learn how a pharma company preparing for a drug launch partnered with MMIT to gain insight into the most effective messaging with payers....
0 Comments
© 2024 MMIT

Meet the Expert: Navigating the Complex U.S. Payer Landscape to Grow Your Business

By MMIT
Understanding a large complex payer and their subsidiaries to segment your contracting plan or recognizing lives enrollment shifts in specific geographies, having payer data source solution to support your sales and...
0 Comments
© 2024 MMIT

Meet the Expert: Tracking Access in Real-Time

By MMIT
Payer coverage policies continue to become more complex with increasing access hurdles. Dig into ways to sift through the noise and uncover payer account intervention and pull-through opportunities via dashboards an...
0 Comments
© 2024 MMIT

Tips to Engage Pharma Manufacturers

By MMIT
Without the right tools, your account managers will face many obstacles trying to win more pharma business. We'll give you our top tips on how to engage with pharma manufacturers and differentiate your organization....
0 Comments
© 2024 MMIT

Neutropenia

By MMIT
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia....
0 Comments
© 2024 MMIT

Financial considerations for Rolontis® (Contracting Pharmacist)

By MMIT
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia....
0 Comments
© 2024 MMIT

What shifts have been observed by Oncologists in the treatment of Neutropenia? (Oncologist 2)

By MMIT
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia....
0 Comments
© 2024 MMIT

Does Neulasta® Onpro® retain any advantages as the only on-body injector? (Oncologist)

By MMIT
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia....
0 Comments
© 2024 MMIT